Tufts CSDD Impact Report on European-Specific Clinical Trial Under-Representation
Tufts CSDD released its May/June Impact report featuring demographic under-representation in clinical trials in Europe. The report summarizes analysis of a dataset made up of 1,731 clinical trials and 943 pivotal trials—representing 446 drugs and biologics—supporting EU Commission approvals of new medicines under the Centralized Procedure between 2007 and 2019. The data were collected using EMA Annual Reports, the annexes to the Annual Reports, the Human Medicines Highlights, EudraCT, European public assessment reports and other public resources.
Highlights include the following:
- During 2007-19, only 64% of pivotal trials supporting the EU Commission approval process reported any data on study participants’ race, and only 29% provided data on ethnicity.
- The percentage of Black participants decreased significantly, while the percentage of Asian participants increased between 2007 and 2019. No significant changes were observed among other demographics.
- Although demographic reporting has increased over time for both EU and FDA, the results in the most recent time period still show a high level of under-reporting.
Click here to go the Tufts CSDD Impact Reports page.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
